Prospective cytomegalovirus monitoring during first-line chemotherapy in patients with acute myeloid leukemia

Journal of Medical Virology

Volumn 82, Issue 7, 2010, Pages 1201-1207

  Capria, Saveria ^a   Gentile, Giuseppe ^a   Capobianchi, Angela ^a   Cardarelli, Luisa ^a   Gianfelici, Valentina ^a   Trisolini, Silvia Maria ^a   Foà, Robin ^a   Martino, Pietro ^a   Meloni, Giovanni ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute myeloid leukemia; CMV; pp65 antigenemia

Indexed keywords

CIDOFOVIR; CYTARABINE; CYTOMEGALOVIRUS ANTIGEN PP65; DAUNORUBICIN; ETOPOSIDE; GANCICLOVIR; HYDROXYUREA; IMMUNOGLOBULIN G; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTIVIRUS AGENT; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; MATRIX PROTEIN; PHOSPHOPROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; REMISSION; VIRUS REACTIVATION; BLOOD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; IMMUNOLOGY; INCIDENCE; ISOLATION AND PURIFICATION; ITALY; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PHYSIOLOGIC MONITORING; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

CYTOMEGALOVIRUS;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CYTARABINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DAUNORUBICIN; FEMALE; HUMANS; HYDROXYUREA; INCIDENCE; ITALY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PHOSPHOPROTEINS; TREATMENT OUTCOME; VIRAL MATRIX PROTEINS; YOUNG ADULT;

EID: 77954409105     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21779     Document Type: Article

References (31)

1. Boeckh M, Ljungman P. 1998. Cytomegalovirus infection after BMT. In: Bowden RA, Ljungman P, Paya CV, editors. Transplant infections. Philadelphia: Lippincott-Raven Publishers. pp 215-217.
2. Boeckh M, Nichols WG. 2003. Immunosuppressive effects of betaherpesviruses. Herpes 10:10-12.
3. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. 1996. Cytomegalovirus pp65 antigenemia-guided early treatment with gancyclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood 88:4063-4071.
4. Chemaly RF, Torres HA, Hachem RY, Nogueras GM, Aguilera EA, Younes A, Luna MA, Rodriguez G, Tarrand JJ, Raad II. 2005. Cytomegalovirus pneumonia in patients with lymphoma. Cancer 104:1213-1220.
5. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ MSG) Consensus Group. Clin Infect Dis 46:1813-1821.
6. Fleiss JL. 1981. Statistical methods for rates and proportions. In: Bradley RA, Hunter JS, Kendall DG, Watson GS, editors. Wiley series in probability and mathematical statistics. New York: John Wiley & Sons, Inc. p 218.
7. Gentile G. 2005. Recent developments in new and old viral infections. Rev Clin Exp Hematol 9:1-15.
8. Gentile G, Micozzi A, Girmenia C, Iori AP, Donati PP, Capria S, Martino P. 1993. Pneumonia in allogenic and autologous bone marrow recipients. A retrospective study. Chest 104:371-375.
9. Gentile G, Picardi A, Capobianchi A, Spagnoli A, Cudillo L, Dentamaro T, Tendas A, Cupelli L, Ciotti M, Volpi A, Amadori S, Martino P, de Fabritiis P. 2006. A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation. BMC Inf Dis 6:167-177.
10. Gerna G, Lilleri D, Baldanti F, Torsellini M, Giorgiani G, Zecca M, De Stefano P, Middeldorp J, Locatelli F, Revello MG. 2003. Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: A prospective, randomized, open-label trial. Blood 101:5053-5060.
11. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoh G, Meyers JD. 1993. Gancyclovir prophylaxis to prevent Cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173-178. (Pubitemid 23034801)
12. Han XY. 2007. Epidemiologic analysis of reactivated cytomegalovirus antigenemia in patients with cancer. J Clin Microbiol 45:1126-1132.
13. Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K, Vimalachandra D, Craig JC. 2005. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomized controlled trials. Lancet 365:2105-2115.
14. Holmberg LA, Boeckh M, Hooper H, Leisenring W, Rowley S, Heimfeld S, Press O, Maloney DG, McSweeney P, Corey L, Maziarz RT, Appelbaum FR, Bensinger W. 1999. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 94:4029-4035.
15. Kalil AC, Levitsky J, Lyden E, Stoner J, Freyfeld AG. 2005. Metaanalysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 143:870-880.
16. Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, Gibran NS, Huang ML, Santo Hayes TK, Corey L, Boeckh M. 2008. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 300:413-422.
17. Ljungman P, Brand R. 2007. Factors Influencing CMV seropositivity in stem cell transplant patients and donors. Haematologica 92:1139-1142. (Pubitemid 350144225)
18. Ljungman P, Griffiths P, Paya C. 2002. Definitions of Cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34: 1094-1097. (Pubitemid 34289682)
19. Ljungman P, Von Dobeln L, Ringholm L, Lewensohn-Fuchs I, Klingspor L, Sparrelid E. 2005. The value of CMV and fungal PCR for monitoring of acute leukemia and autologous stem cell transplant patients. Scand J Infect Dis 37:121-126. (Pubitemid 40298165)
20. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC. 1999. International Valacyclovir Cytomegalovirus Prophylaxis Study Group: Valacyclovir for the prevention of cytomegalovirus disease in renal transplantation. N Engl J Med 340:1462-1470.
21. Meyers JD, Floumony N, Thomas ED. 1986. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 153:478-488.
22. Natali A, Valcalvi P, Medici MC, Dieci E, Montali S, Chezzi C. 1997. Cytomegalovirus infection in an Italian population: Antibody prevalence, virus excretion and maternal transmission. New Microbiol 20:123-133. (Pubitemid 127527392)
23. Ng AP, Worth L, Chen L, Seymour JF, Prince HM, Slavin M, Thursky K. 2005. Cytomegalovirus DNAemia and disease: Incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica 90:1672-1679. (Pubitemid 41814993)
24. Nguyen Q, Estey E, Raad I, Rolston K, Kantarjian H, Jacobson K, Konoplev S, Ghosh S, Luna M, Tarrand J, Whimbey E. 2001. Cytomegalovirus pneumonia in adults with leukaemia: An emerging problem. Clin Infect Dis 32:539-545.
25. Nichols WG, Corey L, Gooley TA, Davis C, Boeckh M. 2002. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection. J Infect Dis 185:273-282.
26. Paulin T, Ringden O, Lonnqvist B, Wahren B, Nilsson B. 1986. The importance of pre bone marrow transplantation serology in determining subsequent cytomegalovirus infection: An analysis of risk factors. Scand J Infect Dis 18:199-209.
27. Persson L, Dahl H, Linde A, Engervall P, Vikerfors T, Tidefelt U. 2003. Human cytomegalovirus, human herpesvirus-6, and human herpesvirus- 7 in neutropenic patients with fever of unknown origin. Clin Microbiol Infect Dis 9:640-644.
28. Reusser P, Fisher LD, Buckner CD, Thomas ED, Meyers JD. 1990. Cytomegalovirus infection after autologous bone marrow transplantation: Occurrence of cytomegalovirus disease and effect on engraftment. Blood 75:1888-1894.
29. Sakamaki H, Yuasa K, Goto H, Tanikawa S, Akiyama H, Onozawa Y, Okamoto R, Maeda Y, Sasaki T, Kaku H, Tsuzuki S, Takamoto S, Mochida Y, Minematsu T, Minamishima Y. 1997. Comparison of cytomegalovirus (CMV) antigenemia and CMV in bronchoalveolar lavage fluid for diagnosis of CMV pulmonary infection after bone marrow transplantation. Bone Marrow Transplant 20:143-147.
30. Torres HA, Kontoyiannis DP, Bodey GP, Adachi JA, Luna MA, Tarrand JJ, Nogueras GM, Raad II, Chemaly RF. 2005. Gastrointestinal disease in patients with cancer: A two decade experience in a tertiary care cancer center. Eur J Cancer 41:2268-2279.
31. Wade J. 1993. Management of infection in patients with acute leukaemia. Hematol Oncol Clin North America 7:293-315.